{
    "id": 50872,
    "name": "large cell neuroendocrine carcinoma",
    "source": "DOID",
    "definition": "A lung large cell carcinoma that derives_from neuroendocrine cells. [url:https\\://www.ncbi.nlm.nih.gov/pubmed/15999058]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:0050872",
    "evidence": [
        {
            "id": 4563,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rovalpituzumab Tesirine treatment resulted in sustained tumor regression in PDX models of large cell neuroendocrine carcinoma with elevated levels of Dll3 protein (PMID: 26311731).",
            "molecularProfile": {
                "id": 18587,
                "profileName": "DLL3 over exp"
            },
            "therapy": {
                "id": 3544,
                "therapyName": "Rovalpituzumab Tesirine",
                "synonyms": null
            },
            "indication": {
                "id": 50872,
                "name": "large cell neuroendocrine carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4615,
                    "pubMedId": 26311731,
                    "title": "A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26311731"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT02936323",
            "title": "PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers",
            "phase": null,
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5819,
                    "therapyName": "PEN-221",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03901378",
            "title": "Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2604,
                    "therapyName": "Carboplatin + Etoposide + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 5145,
                    "therapyName": "Cisplatin + Etoposide + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04079712",
            "title": "Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2068,
                    "therapyName": "Cabozantinib + Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        }
    ]
}